Home / Market News / $IRD
fiscal.ai Corporate Catalyst Impact 65/100 ● positive

RBC Raises Price Target on Opus Genetics to $11 From $9

Nov 11, 2026, 2:10 PM UTC · Primary ticker $IRD

RBC Capital Markets increased its price target for Opus Genetics from $9 to $11, maintaining an 'Outperform' rating but noting 'Speculative Risk'. This adjustment follows the company's recent Q3 financial results and corporate updates, suggesting a positive re-evaluation of its prospects by the analyst.

RBC Capital Markets has raised its price target on Opus Genetics (IRD) from $9 to $11, while reiterating an 'Outperform' rating. This upgrade signals increased analyst confidence in the company's future performance, likely driven by positive developments from its recent third-quarter financial results and corporate updates. For traders, this could lead to short-term positive momentum for IRD as the market reacts to the higher price target. However, the 'Speculative Risk' notation indicates that while the upside potential is recognized, there are inherent uncertainties or volatilities associated with the investment, which long-term investors should consider.

$IRD positive Price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.